A series of fourteen patients with polycythaemia due to hypoxic lung disease has been treated with a combination of phenylhydrazine hydrochloride and pyrimethamine to reduce the haematocrit level, with doses usually of up to 100 mg/day (and rarely up to 150 mg/day) of the former and never more than 12·5 mg/day of the latter. Successful reduction of the haematocrit level was achieved in every case without any significant thrombocytopenia, the lowest level ever occurring being 100,000 platelets/mm in two patients. All the patients were improved symptomatically.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2466136PMC
http://dx.doi.org/10.1136/pgmj.45.527.583DOI Listing

Publication Analysis

Top Keywords

patients polycythaemia
8
polycythaemia hypoxic
8
hypoxic lung
8
lung disease
8
phenylhydrazine hydrochloride
8
hydrochloride pyrimethamine
8
haematocrit level
8
reduction excessive
4
excessive haematocrit
4
haematocrit levels
4

Similar Publications

This case report describes the clinical course of a 78-year-old patient diagnosed with polycythemia vera (PV), who presented with pronounced acrocyanosis of the hands in 2021. The patient was treated with hydroxyurea (oncocarbide), and nailfold capillaroscopy revealed an "abnormal pattern" characterized by pronounced architectural disarray and capillary tortuosity, which is uncommon in patients with myeloproliferative neoplasms (MPNs). In 2023, owing to suboptimal symptom management and hematological side effects, the treatment was switched to ruxolitinib, which led to significant clinical improvements by 2024, including near-complete resolution of acrocyanosis and substantial improvement in capillaroscopic abnormalities, with only residual capillary tortuosity noted.

View Article and Find Full Text PDF

Improving the management of polycythemia vera patients eligible for cytoreduction: report of a multidisciplinary advisory board.

Curr Med Res Opin

January 2025

Section of Hematology, Department of Radiological and Hematological Sciences, Catholic University, Fondazione Policlinico Gemelli IRCCS, Rome, Italy.

Introduction: The management of patients with Polycythemia Vera (PV) traditionally includes low-dose aspirin, phlebotomy, and cytoreductive therapy for high-risk individuals. Recent evidence suggests that cytoreductive treatment may be warranted for patients with additional risk factors beyond the traditional criteria of a history of thrombosis and age over 60 years. Introducing new therapeutic agents, including ropeginterferon alfa-2b and ruxolitinib, enables a more personalized treatment approach tailored to individual patient characteristics.

View Article and Find Full Text PDF

Prevalence and predictive factors of testosterone-induced erythrocytosis: a retrospective single center study.

Front Endocrinol (Lausanne)

January 2025

Department of Internal Medicine, Division of Endocrinology, Diabetes and Clinical Nutrition, Luzerner Kantonsspital, Lucerne, Switzerland.

Aim: This study analyzes the prevalence and predictive factors of testosterone-induced erythrocytosis (TIE) in patients receiving testosterone replacement therapy (TRT).

Methods: Retrospective single-center observational study.

Results: 247 patients were included; median age was 47.

View Article and Find Full Text PDF

Associations Between Blood Hemoglobin Concentrations and Cardiometabolic Risk in Middle-Aged Women.

Womens Health Rep (New Rochelle)

January 2025

Department of Preventive Medicine, School of Medicine, Hyogo Medical University, Nishinomiya, Japan.

Objective: Patients with polycythemia have a high risk of thrombo-atherosclerotic diseases. However, it remains to be clarified whether a high blood hemoglobin level is related to cardiometabolic risk in women.

Methods: The overall subjects were 18,410 middle-aged women who had received health checkup examinations at their workplaces.

View Article and Find Full Text PDF

Deciphering the complex clonal heterogeneity of polycythemia vera and the response to interferon alpha.

Blood Adv

January 2025

Department of Hematology, Oncology, Hemostaseology, and Stem Cell Transplantation, Medical Faculty, RWTH Aachen University, Aachen, Germany.

Interferon alpha (IFNa) is approved for the therapy of patients (pts) with polycythemia vera (PV), a subtype of myeloproliferative neoplasms (MPN). Some pts achieve molecular responses (MR), but clonal factors sensitizing for MR remain elusive. We integrated colony formation and differentiation assays with single-cell RNA seq and genotyping in PV-derived cells vs.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!